Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

CANbridge to commercialize GC Pharma's Hunterase in China

Executive Summary

GC Pharma (formerly known as Green Cross Corp.) granted CANbridge Life Sciences Ltd. exclusive Chinese commercialization rights to its Hunterase (GC1111; iduronate-2-sulfatase (IDS)) for Hunter syndrome (mucopolysaccharidosis Type II; MPS II).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register